Share >  
Share
Share on Tumblr

Balaglitazone

News »

   latest by relevance
Dr Reddy's anti-diabetes drug in trouble
Feb 04, 2011 at 21:11 | Source: CNBC-TV18
The launch of Dr Reddy's anti-diabetes drug - Balaglitazone is in danger, reports CNBC-TV18.
Dr Reddy's says diabetic drug trial successful
Jan 05, 2010 at 08:29 | Source: Reuters
Drugmaker Dr Reddy's Laboratories said on Monday phase III clinical trial for its anti-diabetic molecule balaglitazone, being conducted by Danish firm Rheoscience, had achieved the set parameters.
Dr Reddy's positive on Phase III trial of diabetes drug
Jan 04, 2010 at 21:44 | Source: CNBC-TV18
Dr Reddy's Laboratories has announced results of its Phase III trial of Balaglitazone, a drug used for treatment of Type II diabetes.
Balaglitazone R&D costs to be shared by co-developer: DRL
Dec 04, 2007 at 15:16 | Source: CNBC-TV18
Saumen Chakraborty, CFO, Dr Reddy's Labs said that the Betapharm side of the business faced supply problems from Salutas and added that they have now reduced their dependence on Salutas. On R&D expenses incurred on Balaglitazone which is in phase III of clinical trials, he said they are being shared by the co-developers.
Dr Reddys new diabetic drug to hit market in 2011
Nov 16, 2007 at 08:30 | Source: Business Line
Balaglitazone, a new diabetic drug candidate of Dr Reddys Laboratories, is currently undergoing phase III clinical trails and will hit the market by 2011, according to Mr K. Anji Reddy, Founder-Chairman, Dr Reddys Laboratories Ltd.
Capex, dividend payout led to fall in Q2 cash levels: DRL
Oct 24, 2007 at 20:09
Dr Reddy's Laboratories has announced its second quarter numbers. It has posted consolidated net profit of Rs 267.2 crore for the quarter ended September 2007 as against Rs 279.8 crore in same quarter of last year (US GAAP).

Videos »
Dr Reddy's anti-diabetes drug in trouble
Dr Reddy's positive on Phase III trial of diabetes drug
Balaglitazone R&D costs to be shared by co-developer: DRL
Capex, dividend payout led to fall in Q2 cash levels: DRL
Dr Reddys to launch diabetes drug by 2011
more »

Photos »

  /  
News across the web »
Glenmark Pharma - The persevering innovator
Glenn Saldanha, chairman, Glenmark Pharmaceuticals Ltd Every Tuesday, unmindful of the gridlocked traffic, Glenn Saldanha, the 41-year-old Chairman of Glenmark Pharmaceuticals Ltd, or GPL, makes it a...
Jan 09, 2012 at 14:31 | Source: Business Today
Opening Bell 20 December
Mumbai: The focus remains on the European Union and its ability to tackle the debt crisis. Overnight, US indices closed in the red after a speech by European Central Bank President Mario Draghi dampen...
Dec 20, 2011 at 09:51 | Source: Livemint
Dr Reddy’s exits drug research
Dr. Reddy’s Laboratories Ltd has exited diabetes and cardiovascular drug research citing the high cost of running clinical trials.“Even the largest of the large companies are moving away from thes...
Dec 20, 2011 at 03:43 | Source: Livemint
Dr Reddy's anti-diabetes drug in trouble
The launch of Dr Reddy's anti-diabetes drug - Balaglitazone is in danger, reports CNBC-TV18. Dr Reddy's Laboratories founder chairman Dr Anji Reddy says that after a similar drug - Avandia - was bann...
Feb 04, 2011 at 22:45 | Source: Moneycontrol
more »

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window